Single-ascending Oral Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-281959 / ACT-246475 in Healthy Male Subjects

NCT01954615 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics

Interventions

DRUG: 5 mg ACT-281959 prodrug formulation I (Group A)
DRUG: 20 mg ACT-281959 prodrug formulation I (Group B)
DRUG: ACT-281959 prodrug formulation I (Groups C to G doses to be defined)
DRUG: ACT-281959 prodrug formulation II (Group G dose to be defined)
DRUG: ACT-246475 (Group G dose to be defined)
DRUG: Placebo (Groups A to F)

Sponsor

Idorsia Pharmaceuticals Ltd.